Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$9.20 USD

9.20
1,564,012

+0.24 (2.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $11.01 +1.81 (19.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Incyte's Application for Pemigatinib Gets EMA's Validation

by Zacks Equity Research

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.

Nalak Das headshot

5 Top Value Picks to Counter Recent Stock Market Softness

by Nalak Das

The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.

Emergent Biosolutions (EBS) Down 4.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EBS or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EBS vs. ILMN: Which Stock Is the Better Value Option?

Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

by Zacks Equity Research

Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

Emergent Biosolutions (EBS) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 92.06% and 14.49%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

by Zacks Equity Research

Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.

Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

by Zacks Equity Research

Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.

Company News For Sep 4, 2019

by Zacks Equity Research

Companies in the news are: CONN, MDCO, EBS and RCL

Emergent Biosolutions (EBS) Down 0.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent's Vaccine Portfolio Aids Growth Amid Competition

by Zacks Equity Research

Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.

Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates

by Zacks Equity Research

Emergent's (EBS) earnings miss estimates in the second quarter of 2019 while revenues surpass the mark.

Emergent Biosolutions (EBS) Q2 Earnings Lag Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25.00% and 14.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Emergent Biosolutions (EBS) Q2 Earnings Expected to Decline

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent (EBS) Wins HHS Contract to Supply VIGIV Product

by Zacks Equity Research

Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.

Why Is Emergent Biosolutions (EBS) Down 23.4% Since Last Earnings Report?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

New Strong Sell Stocks for May 3rd

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Emergent Biosolutions (EBS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -200.00% and -6.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study

by Zacks Equity Research

Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.

Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

by Zacks Equity Research

Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

Emergent Biosolutions (EBS) Down 24.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent Begins Phase III Study on Anthrax Vaccine AV7909

by Zacks Equity Research

Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.